Vernakalant
From Wikipedia, the free encyclopedia
 |
|
|
Vernakalant
|
|
| Systematic (IUPAC) name | |
| (3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl) ethoxy]cyclohexyl}pyrrolidin-3-ol |
|
| Identifiers | |
| CAS number | 748810-28-8 (HCl) |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C20H31NO4 |
| Mol. mass | 349.464 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous |
Vernakalant (INN; codenamed RSD1235, proposed tradename Kynapid) is an investigational drug under regulatory review for the acute conversion of atrial fibrillation.
It is being developed by Cardiome Pharma Corp.
On December 11, 2007, the Cardiovascular and Renal Drugs Advisory Committee of the US Food and Drug Administration voted to recommend the approval of vernakalant.[1]
An oral formulation is currently undergoing Phase II clinical studies.
[edit] References
- ^ FDA Advisory Committee Recommends Approval of Kynapid for Acute Atrial Fibrillation. Drugs.com. Retrieved on 2008-03-15.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
